WO2001081368A3 - Polypeptides reduisant la tension sanguine et contenant vpp derives a partir de micro-organismes - Google Patents

Polypeptides reduisant la tension sanguine et contenant vpp derives a partir de micro-organismes Download PDF

Info

Publication number
WO2001081368A3
WO2001081368A3 PCT/US2001/012776 US0112776W WO0181368A3 WO 2001081368 A3 WO2001081368 A3 WO 2001081368A3 US 0112776 W US0112776 W US 0112776W WO 0181368 A3 WO0181368 A3 WO 0181368A3
Authority
WO
WIPO (PCT)
Prior art keywords
microorganisms
blood
derived
pressure reducing
polypeptides containing
Prior art date
Application number
PCT/US2001/012776
Other languages
English (en)
Other versions
WO2001081368A2 (fr
Inventor
Joseph M Kobzeff
Original Assignee
Monsanto Technology Llc
Joseph M Kobzeff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monsanto Technology Llc, Joseph M Kobzeff filed Critical Monsanto Technology Llc
Priority to AU2001255501A priority Critical patent/AU2001255501A1/en
Publication of WO2001081368A2 publication Critical patent/WO2001081368A2/fr
Publication of WO2001081368A3 publication Critical patent/WO2001081368A3/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18Carboxylic ester hydrolases (3.1.1)
    • C12N9/20Triglyceride splitting, e.g. by means of lipase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne un procédé de production d'un tripeptide VPP anti-hypertenseur. L'invention concerne également des compositions pharmaceutiques, nutritionnelles et alimentaires comprenant VPP en tant que principe actif.
PCT/US2001/012776 2000-04-21 2001-04-19 Polypeptides reduisant la tension sanguine et contenant vpp derives a partir de micro-organismes WO2001081368A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001255501A AU2001255501A1 (en) 2000-04-21 2001-04-19 Blood-pressure reducing polypeptides containing vpp derived from microorganisms

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19968000P 2000-04-21 2000-04-21
US60/199,680 2000-04-21

Publications (2)

Publication Number Publication Date
WO2001081368A2 WO2001081368A2 (fr) 2001-11-01
WO2001081368A3 true WO2001081368A3 (fr) 2002-05-16

Family

ID=22738560

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/012776 WO2001081368A2 (fr) 2000-04-21 2001-04-19 Polypeptides reduisant la tension sanguine et contenant vpp derives a partir de micro-organismes

Country Status (2)

Country Link
AU (1) AU2001255501A1 (fr)
WO (1) WO2001081368A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI411441B (zh) * 2003-03-18 2013-10-11 Suntory Holdings Ltd 血管收縮素轉化酶抑制性肽類
US20070207944A1 (en) * 2004-07-12 2007-09-06 Luppo Edens Blood Pressure Lowering Oligopeptides
CN101084004A (zh) * 2004-12-22 2007-12-05 帝斯曼知识产权资产管理有限公司 单个酶促步骤中的血压降低寡肽
US20090042809A1 (en) * 2005-04-28 2009-02-12 Luppo Edens Blood Pressure Lowering Protein Hydrolysates

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0583074A2 (fr) * 1992-07-23 1994-02-16 The Calpis Food Industry Co., Ltd. Inhibiteur de l'enzyme de conversion de l'angiotensine et procédé pour le préparer
WO1996017054A1 (fr) * 1994-12-01 1996-06-06 Oklahoma Medical Research Foundation Technique et compositions permettant de reduire l'absorption de cholesterol
WO1996037622A1 (fr) * 1995-05-24 1996-11-28 Astra Aktiebolag (Publ) Molecules d'adn pour l'expression de la lipase stimulee par les sels biliaires (bssl)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0583074A2 (fr) * 1992-07-23 1994-02-16 The Calpis Food Industry Co., Ltd. Inhibiteur de l'enzyme de conversion de l'angiotensine et procédé pour le préparer
WO1996017054A1 (fr) * 1994-12-01 1996-06-06 Oklahoma Medical Research Foundation Technique et compositions permettant de reduire l'absorption de cholesterol
WO1996037622A1 (fr) * 1995-05-24 1996-11-28 Astra Aktiebolag (Publ) Molecules d'adn pour l'expression de la lipase stimulee par les sels biliaires (bssl)

Also Published As

Publication number Publication date
WO2001081368A2 (fr) 2001-11-01
AU2001255501A1 (en) 2001-11-07

Similar Documents

Publication Publication Date Title
AU7038600A (en) Extracts derived from pueraria mirifica, butea superba and/or mucuna collettii and extraction thereof
WO2001058412A3 (fr) Extraits de residus de la production de vin
EP1293503A4 (fr) Derives de triazole
ZA200203867B (en) alpha-Amino acids compounds, a process for their preparation and pharmaceutical compositions containing them.
AP2003002916A0 (en) HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis.
CA2567582A1 (fr) Complement dietetique anti-hypertensif derive d'hydrolysats de proteines de saumon ou d'oncorhynchus
HK1067626A1 (en) Novel 2h-pyridazine-3-one derivatives, pharmaceutical compositions containing the same and a process for the preparation of the active ingredient
HUP0200623A3 (en) 4,5-diaryl-3(2h)-furanone derivatives as cyclooxygenase-2 inhibitors and pharmaceutical compositions containing them
EP1550448A4 (fr) Inhibiteur de la liberation d'histamine
AU2002243005A1 (en) Vital cell preparations containing lactic acid bacterium as the active ingredient and lactic acid bacterium-containing foods
CA2450093A1 (fr) Polymorphe stable de flibanserine, procede de preparation associe et utilisation dudit polymorphe dans la preparation de medicaments
WO2003087050A3 (fr) Sel de perindopril et les compositions pharmaceutiques qui le contiennent
CA2431998A1 (fr) Concentres d'arome
AU2002238855A1 (en) N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
WO2002056708A3 (fr) Preparation destinee a ameliorer l'assimilation des aliments
HUP0400155A3 (en) N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
WO2003099192A8 (fr) Alcanols bi-aromatiques
WO2001080873A3 (fr) Peptide de modulation du recepteur de la thrombopoietine
MXPA03008420A (es) Forma farmaceutica solida oralmente dispersa.
EE05491B1 (et) Leeliselist sfingomelinaasi sisaldav kompositsioon kasutamiseks dieteetilise valmistise, toidulisandi v?i farmatseutilise tootena
WO2004031202A3 (fr) Palatinose condense sous forme hydrogenee
AU2002241408A1 (en) Modular system of dietary supplement compositions comprising vitamins
WO2003049687A3 (fr) Compositions medicinales et methodes therapeutiques
WO2001081368A3 (fr) Polypeptides reduisant la tension sanguine et contenant vpp derives a partir de micro-organismes
AU2003302188A1 (en) Method of obtaining a soothing active ingredient, active ingredient and compositions obtained

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP